Stay updated on Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.

Latest updates to the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page
- Check6 days agoChange DetectedAdded revision: v3.4.3 and removed revision: v3.4.2. This is a metadata version update.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.4.2 was added. The prior lapse-in-government-funding operating-status notice was removed.SummaryDifference0.4%

- Check42 days agoChange DetectedA site-wide funding/operating status notice has been added, and the site version has been updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check49 days agoChange DetectedThe page now shows a glossary option and includes meta-data updates: the 'Last Update Submitted that Met QC Criteria' label and a 'No FEAR Act Data' note were added, and the site revision updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No changes to study content or critical functionality were observed.SummaryDifference0.1%

- Check85 days agoChange DetectedAdded a Locations section highlighting Texas (Houston, MD Anderson Cancer Center) for the study, removed the old Texas Locations block and the HHS Vulnerability Disclosure link, and updated the revision to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.